# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price tar...
CalciMedica (NASDAQ:CALC) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.53) b...
Oppenheimer analyst Leland Gershell maintains CalciMedica (NASDAQ:CALC) with a Outperform and raises the price target from $...
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price tar...
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company foc...
HC Wainwright & Co. analyst Joseph Pantginis reiterates CalciMedica (NASDAQ:CALC) with a Buy and maintains $20 price tar...